High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity

Immunity. 2022 Oct 11;55(10):1953-1966.e10. doi: 10.1016/j.immuni.2022.09.004. Epub 2022 Sep 28.

Abstract

A major challenge in adoptive T cell immunotherapy is the discovery of natural T cell receptors (TCRs) with high activity and specificity to tumor antigens. Engineering synthetic TCRs for increased tumor antigen recognition is complicated by the risk of introducing cross-reactivity and by the poor correlation that can exist between binding affinity and activity of TCRs in response to antigen (peptide-MHC). Here, we developed TCR-Engine, a method combining genome editing, computational design, and deep sequencing to engineer the functional activity and specificity of TCRs on the surface of a human T cell line at high throughput. We applied TCR-Engine to successfully engineer synthetic TCRs for increased potency and specificity to a clinically relevant tumor-associated antigen (MAGE-A3) and validated their translational potential through multiple in vitro and in vivo assessments of safety and efficacy. Thus, TCR-Engine represents a valuable technology for engineering of safe and potent synthetic TCRs for immunotherapy applications.

Keywords: T cell receptor; TCR; deep sequencing; immunotherapy; protein engineering.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm
  • Humans
  • Immunotherapy
  • Immunotherapy, Adoptive*
  • Peptides
  • Receptors, Antigen, T-Cell*

Substances

  • Antigens, Neoplasm
  • Peptides
  • Receptors, Antigen, T-Cell